United Imaging Healthcare Co. Ltd. (UIH) presented its Umr Jupiter 5.0T scanner at the European Congress of Radiology in Vienna. This new ultra-high-field 5 Tesla MRI scanner supports exclusive whole-body clinical and research applications.
Doctorly GmbH raised $10 million in a series A funding round to revamp the German health care sector, giving medical staff new tools to eliminate disk operating systems (DOS).
Implantica AG reported that the first two Refluxstop procedures to treat acid reflux have been performed at Getafe University Hospital in Spain. Trial results indicate that the single-use passive medical implant can cure reflux in 98% of cases without the need for medication.
Proteor SAS is launching the Synsys bionic leg, a sensor-equipped microprocessor-controlled knee-ankle-foot prosthetic leg for above-the-knee amputees. This new generation prosthesis coordinates knee and ankle movements simultaneously as an extension of the hip, enabling smoother, more natural movement on a variety of surfaces.
Coloplast A/S is about to launch a new single-use male intermittent catheter featuring new technology designed to reduce the risk of urinary tract infections (UTI). “The Luja device, with its micro-hole zone technology, is going to drive future growth in our continence care division,” Coloplast Chief Financial Officer Anders Lonning Skovgaard told BioWorld.
The France Biotech business association released its latest annual survey covering the health-tech sector in France. According to the 2022 edition of the Panorama, 1,440 med-tech, 880 bio-tech and 4,000 health and artificial intelligence software companies have been surveyed, responsible between them for $1.4 billion in sales revenues and 14,000 direct jobs, not counting the 2,200 new jobs planned for 2023 mainly in R&D, production and support services.
Elypta AB has devised new multi-cancer early detection technology leveraging plasma and urine glycosaminoglycans which can detect more than a dozen types of cancer in adults showing no symptoms.
Affluent Medical SA reported the imminent raising of nearly $14 million to fund development throughout 2023 of its implantable medical devices for treating urinary incontinence and heart valve pathology. Affluent, quoted on the Paris Euronext stock exchange since 2021, issued new shares accompanied by redeemable share warrants with shareholder preferential subscription rights being preserved.
Avicenna.AI SAS secured a further $7.5 million in series A funding, bringing the total aggregated investment in the company so far to $10.4 million. The round was backed by the two existing Paris-based investors: Cemag Invest SAS and Innovacom Gestion SAS. “Thanks to this funding, we are now able to ramp deployment of our software platform around the world, as well as diversify our offering into new areas of medicine,” Cyril Di Grandi, CEO and co-founder of Avicenna.AI SAS, told BioWorld.
